The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM
Clinical trial NCT03686254 · UNKNOWN
Trial details
- NCT number
- NCT03686254
- Sponsor
- Nanfang Hospital, Southern Medical University
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-16
- Primary completion
- 2023-10-01
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.